价格

Eli Lilly Nederland BV

ACTIVE

荷兰www.lilly.com/nlSubsidiary

隶属于 Eli Lilly & Co.

概览

试验阶段分布

阶段

试验数

占比

2 期

100.0%

试验状态分布

招募中

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

139

药物批准

近期批准

CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION

CIMA_AEMPS

2026-09-08

CYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION

CIMA_AEMPS

2026-09-08

ONSWIK 1000 UNIDADES/ML SOLUCION INYECTABLE EN PLUMA PRECARGADA

CIMA_AEMPS

2026-09-01

ONSWIK 500 UNIDADES/ML SOLUCION INYECTABLE EN PLUMA PRECARGADA

CIMA_AEMPS

2026-09-01

RETSEVMO 80 MG CAPSULAS DURAS

CIMA_AEMPS

2026-05-13

RETSEVMO 40 MG CAPSULAS DURAS

MOUNJARO 2,5 MG/DOSIS KWIKPEN SOLUCION INYECTABLE EN PLUMA PRECARGADA

资讯

暂无资讯文章

返回机构列表

Eli Lilly Nederland BV

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（1）

A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

药物批准

按机构分类的批准

近期批准

资讯